(Q42801530)

7 November 2017

title

Targeting of endothelial KDR receptors with 3G2 immunoliposomes in vitro (English)

1 reference

7 November 2017

0 references

P Benzinger

1

1 reference

7 November 2017

G Martiny-Baron

2

1 reference

7 November 2017

P Reusch

3

1 reference

7 November 2017

G Siemeister

4

1 reference

7 November 2017

J T Kley

5

1 reference

7 November 2017

D Marmé

6

1 reference

7 November 2017

C Unger

7

1 reference

7 November 2017

U Massing

8

1 reference

7 November 2017

publication date

1 June 2000

1 reference

Biochimica et Biophysica Acta

7 November 2017

published in

1 reference

7 November 2017

volume

1466

1 reference

7 November 2017

issue

1-2

1 reference

7 November 2017

page(s)

71-78

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

7 November 2017

1 reference

Engineering liposomes for drug delivery: progress and problems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

Tumour targeting with antibody-coupled liposomes: failure to achieve accumulation in xenografts and spontaneous liver metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

Design of immunoliposomes directed against human ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

7 January 2021

Immunoliposomes in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

Angiogenesis in cancer, vascular, rheumatoid and other disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

VEGF-mediated tumour angiogenesis: a new target for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

Ellman's reagent: 5,5′-dithiobis(2-nitrobenzoic acid)—a reexamination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

A new, sensitive determination of phosphate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

Liposomes for the sustained drug release in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

Long circulating, cationic liposomes containing amino-PEG-phosphatidylethanolamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

Expression of biologically active isoforms of the tumor angiogenesis factor VEGF in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

Antiangiogenesis for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0005-2736%2800%2900172-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0005-2736(00)00172-3

1 reference

7 November 2017

1 reference